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Ovarian epithelial cancer (OEC) is the most common form of 
malignancy and the leading cause of cancer death involving the 
female genital tract as well as the fifth most common cause of 
cancer-related death among women in the United States.1 Al-
though there have been major advances in cancer treatment, the 
survival rate of OEC has not improved significantly in the last 
few decades. OEC frequently remains clinically silent, and the 
majority of patients with OEC present for diagnosis at an ad-
vanced stage.2 To improve the assessment of a patient’s risk of 
disease progression, several parameters, including patient age, 
disease stage, residual tumor mass, tumor type, and histologic 
grade, have been shown to have a prognostic value in OEC.3
Epithelial-mesenchymal transition (EMT) is a vital process 
during embryonic development in which epithelial cells lose 
cell-cell adhesion and acquire mesenchymal properties and a 
migratory phenotype. It is essential for numerous developmen-
tal processes, such as neural tube formation and wound healing 
in organ fibrosis. Nevertheless, an appreciation of the role EMT 
plays in tumor metastasis is relatively new.4 TWIST was first 
identified in Drosophila melanogaster and is a basic helix-loop-he-
lix transcription factor that induces motility and metastatic po-
tential in several tumors by promoting EMT.5 The role of 
TWIST proteins in cancer has been investigated over the course 
of the last decade. It has been found that TWIST is a central 
player in the EMT of many cancers,6 including breast,7 ovari-
an,8,9 endometrial,10 bladder,11 lung,12 gastric,13 pancreatic,14 
prostate,11 thyroid,15 and head and neck squamous cell carcino-
mas (HNSCC).16 In all cancer types, the expression of TWIST 
is associated with poor prognosis, and high-grade, invasive, and 
metastatic lesions. TWIST protein promotes EMT by turning 
down the expression of epithelial-specific proteins, such as E-
cadherin, a hallmark of EMT.17 Recently, a novel function of 
TWIST has been reported in the development of acquired che-
moresistance in human cancer cells.18
Tumor hypoxia has been linked to an aggressive phenotype 
that correlates with cancer metastasis and chemoresistance in var-
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ious solid malignancies.19 Hypoxia-inducible factor 1α (HIF1α) 
is one of the key factors regulating cellular responses to hypoxia. 
HIF1α overexpression has been reported in a variety of human 
cancers, and is correlated with aggressive tumor phenotypes, 
therapeutic resistance, and poor prognosis. HIF1α and HIF1α-
regulated genes also promote EMT, a critical step in metastasis. 
Co-expression of HIF1α and TWIST has been shown, and could 
be used as a prognostic marker in cancer patients.12,20,21
TWIST may be involved in several pathways that contribute 
to carcinogenesis, including interference of the p53-associated 
pathway involved in apoptosis, as well as EMT-related path-
ways.18 p53 is one of the most frequently mutated tumor sup-
pressor genes and is more commonly altered in advanced cases of 
ovarian cancer.22 Mutation in p53 or p53 inactivation correlates 
with altered expression of EMT markers such as TWIST and E-
cadherin.23 Recent evidence indicates that TWIST has been 
shown to reduce the activity of p53 through a complex network 
of post-translational modifications and molecular interactions 
inﬂuenced by several signaling pathways. These findings suggest 
the involvement of p53 in the regulation of the EMT pathway.24
Recent studies in OEC have supported the role of EMT in 
ovarian carcinogenesis.8,9 Overexpression of TWIST plays a role 
not only in the development of ovarian carcinoma, but also in 
patient survival. We examined the expression of TWIST by im-
munohistochemistry in a panel of 123 OEC patients. We also 
evaluated the expression of E-cadherin, HIF1α, and p53. We 
aimed to investigate the association of these factors with clini-
copathologic features and their impact on patient survival.
MATERIALS AND METHODS
Patients and tissue samples
The OEC tissue samples were obtained during surgical opera-
tions performed at Pusan National University Hospital, Korea, 
from 1999 to 2008. A total of 123 patients (mean age, 49.5 
years; range, 15 to 82 years) who underwent surgical resection 
for OEC were examined. Pathological data, such as pathologic 
stage, tumor grading, tumor size, mitosis, and histological tu-
mor type, were obtained from the primary pathology reports, 
and patient chart reviews were performed retrospectively. His-
tologic tumor type and grade were determined according to the 
World Health Organization criteria. The criteria of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO) were 
used to classify cases as stages I–IV. All patients, except those 
with grade 1, stage IA, were given adjuvant chemotherapy of 
platinum/taxol-containing drugs. The patients were followed 
up from the date of surgery until death or the last visit to the 
outpatient department. The follow-up period ranged from one 
to 175 months (median, 49 months). Overall survival (OS) was 
calculated from the date of surgery to the date of death or last 
followup visit. Progression-free survival (PFS) was calculated 
from the date of surgery to the date of tumor progression or re-
lapse, including local recurrence and/or metastasis. The patients’ 
demographic and tumor characteristics are presented in Table 1. 
This study was approved by the Ethics Committee of the Pusan 
National University Hospital, and informed consent was ob-
tained from all the patients.
Immunohistochemistry
Immunohistochemistry was performed on serial 4-µm-thick 
paraffin sections. The slides were deparaffinized in xylene and re-
hydrated through four decreasing grades of ethanol (100%, 
95%, 80%, and 70%) for 2 minutes each. Endogenous peroxi-
dase activity was blocked by immersing the slides in 3% hydro-
gen peroxide in methanol for 15 minutes at room temperature. 
Heat-induced antigen retrieval was performed for 5 minutes 
with 1×  citrate buffer (pH 6.3) using a microwave and then 
cooled for 5 minutes. This process was performed three times. In 
order to reduce the nonspecific binding of antibodies to the tis-
Table 1. Clinicopathological features of the ovarian epithelial can-
cer patients
Parameter n (%) (n=123)
Histologic type Serous 63 (51.2)
Mucinous 24 (19.5)
Endometrioid 11 (8.9)
Clear cell 25 (20.4)
Histologic grade Well differentiated (G1) 35 (28.5)
Moderately differentiated (G2) 62 (50.4)
Poorly differentiated (G3) 26 (21.1)
Nuclear grade 1 13 (10.6)
2 62 (50.4)
3 48 (39.0)
Mitoses <10/10 HPF 52 (42.3)
10–19/10 HPF 41 (33.3)
≥20/10 HPF 30 (24.4)
Size (cm) <10 58 (47.2)
≥10 65 (52.8)
FIGO stage I 55 (44.7)
II 8 (6.5)
III 43 (35.0)
IV 17 (13.8)
Disease progression No 63 (51.2)
Yes 60 (48.8)
Overall survival Alive 73 (59.3)
DOD 50 (40.7)
HPF, high power field; FIGO, Federation of Gynecology and Obstetrics; 
DOD, died of disease.
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sues, the slides were preincubated with blocking serum in 1% 
bovine serum albumin for 30 minutes at room temperature. The 
slides were left to incubate with rabbit polyclonal anti-TWIST 
antibody (1:200, Santa Cruz Biotechnology, San Diego, CA, 
USA), mouse monoclonal anti-E-cadherin antibody (1:400, In-
vitrogen, Carlsbad, CA, USA), mouse monoclonal anti-HIF1α 
antibody (1:1,000, Novus Biologicals, Littleton, CO, USA), and 
rabbit monoclonal anti-p53 antibody (1:200, Thermo Scientific, 
San Jose, CA, USA) overnight at 4°C. After incubation with the 
primary antibodies, the slides were rinsed with phosphate-buff-
ered saline for 10 minutes. Thereafter, for the detection of the 
antibody reactions, the EnVision Detection System (Dako, Car-
pinteria, CA, USA) was used. The color was developed using di-
aminobenzidine. Finally, the sections were counterstained with 
Mayer’s hematoxylin solution for 1 minute, and dehydrated with 
graded alcohols, dipped in two changes of xylene, and mounted.
Assessment of immunohistochemical staining
The immunohistochemical staining was assessed with a light 
microscope by two pathologists who had no prior knowledge of 
the clinical data. For TWIST and HIF1α, only nuclear staining 
was considered with a 10% cut-off value for positivity.7 For E-
cadherin, membrane staining was graded from 0–3: 0, no stain-
ing or weak intensity in 10% of the tumor cells; 1, low intensity 
in 10% of the tumor cells; 2, moderate intensity in 10% of the 
tumor cells; and 3, strong intensity in 10% of the tumor cells. 
The cases were divided into two groups: preserved E-cadherin 
expression (score 3) or reduced E-cadherin expression (scores 0, 1, 
and 2).21 p53 was recognized through nuclear staining of the 
positive cells. The results were divided into two groups: positive 
(≥30% positive tumor cells) and negative (<30% positive tu-
mor cells).25
Statistical analysis
All statistical analyses were performed using SPSS ver. 19.0 
(IBM Co., Armonk, NY, USA). Pearson’s chi-squared test was 
used to study the associations between the clinicopathological 
factors and immunohistochemical markers. The linear correla-
tions for protein expression were assessed using the Sperman’s 
rank test. OS was calculated from the date of surgery to the date 
of death or last follow-up visit to the outpatient department. 
PFS was calculated from the date of surgery to the date of tumor 
relapse or progression. Data on patients who had survived until 
the end of the observation period were censored at their last fol-
low-up visit. Death from a cause other than ovarian cancer and 
cases lost to follow-up were considered censoring events. The ef-
fect of immunohistochemical markers on survival was assessed 
using Kaplan-Meier survival curves and a log-rank test. Multi-
variate survival analyses were calculated using Cox’s proportion-
al hazards model. For all the tests, a p-value ≤ .05 was consid-
ered to be significant.
RESULTS
Altered expression of HIF1α, E-cadherin, TWIST, and p53 in 
relation to clinicopathologic parameters
Expression of HIF1α, TWIST, and p53 proteins was detected 
in 35 (28.5%), 43 (35.0%), and 36 (29.3%) of the 123 OEC 
cases, respectively. Reduced expression of E-cadherin was ob-
served in 60 cases (48.8%). Specific staining for TWIST was ob-
served in the nucleus of tumor cells, but in some cases, both nu-
clear and cytoplasmic staining was observed. There was little 
immunoreactivity for TWIST in the tumor stroma. E-Cadherin 
expression was membranous, and occasionally cytoplasmic. Rep-
resentative images of immunostaining are shown in Fig. 1.
TWIST expression was associated with higher histologic tu-
mor grades (p=.004). Clear cell types exhibited TWIST expres-
sion more frequently than other histologic types, but this was 
not statistically significant (p=.240). Reduced E-cadherin ex-
pression was more commonly found in the advanced stages of 
OEC (38 of 60 cases, 63.3%) than the early stages (22 of 63 
case, 34.9%) (p=.002). HIF1α showed different expression ac-
cording to histologic tumor type but was not associated with 
any clinicopathological parameters. There was a statistically 
significant increase in the expression of p53 in serous-type OEC 
compared with other types (p=.000). There were also positive 
correlations between p53 and the histologic tumor grade, FIGO 
stage, and mitotic rate (Table 2).
TWIST expression was significantly correlated with reduced 
E-cadherin expression (p=.000, correlation coefficient [c.c.]= 
–0.309) and increased HIF1α expression (p=.000, c.c.=0.532). 
TWIST expression was not correlated with the expression of 
p53 (p=.142, c.c.=0.168). There was a negative correlation 
between p53 expression and the reduced expression of E-cad-
herin (p=.041, c.c.=–0.219) (Table 3).
Correlation between TWIST, E-cadherin, HIF1α, and p53 
expressions and survival
Follow-up data were available for 123 patients (median, 49 
months; range, 1 to 175 months). Fifty patients (40.7% of 123 
patients) died from the disease during the follow-up period. 
Sixty patients (48.8%) developed either recurrence or metastasis 
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(progression group), whereas 63 patients (51.2%) remained free 
of progression (progression-free group). The univariate analysis 
showed that tumor histologic grade, tumor stage, mitotic rate, 
positive expression of TWIST and p53, and reduced expression 
of E-cadherin were associated with poor OS and PFS. Serous 
type and tumor size were also correlated with poor PFS (Table 4, 
Fig. 2).
We tried to explore whether the combined expression of these 
protein markers had any prognostic value. Eighteen of 27 pa-
tients (66.7%) who had a pattern of positive TWIST expression 
and reduced expression of E-cadherin [TWIST(+)/E-cadherin(–) 
group] died of disease, compared to 32 of 96 patients (33.3%) 
without a pattern of TWIST(+)/E-cadherin(–) (p=.003). Of 19 
patients showing an altered HIF1α/TWIST/E-cadherin pathway 
with positive expression of HIF1α and TWIST, and reduced E-
cadherin expression, 13 (68.4%) died of disease, whereas 37 of 
104 patients (35.6%) without an altered HIF1α/TWIST/E-cad-
herin pathway died of disease (p=.011). Thirteen of 14 patients 
(92.9%) who displayed expression of both TWIST and p53 
showed disease progression compared to 47 of 109 patients 
(43.1%) who had no expression of TWIST or p53. This differ-
ence was statistically significant (p=.000). In a multivariate 
analysis with the variables defined in Table 5, positive expression 
of TWIST was associated with lower OS after adjustment for 
histologic grade, tumor stage, mitotic rate, p53 expression, and 
altered expression of the HIF1α/TWIST/E-cadherin pathway, 
which were significant parameters in the univariate analysis.
DISCUSSION
The EMT, which is considered to be one of the major mecha-
nisms underlying tumor invasion and metastasis, has been 
studied to understand how epithelial cancer cells can acquire 
the ability to migrate and metastasize. EMT is triggered by a 
set of stimuli, which include hypoxia and growth factors, and 
tumor stromal cell interactions with transcription factors such 
A B
C D
Fig. 1. Expression of TWIST, hypoxia-inducible factor 1α (HIF1α), p53, and E-cadherin in ovarian epithelial cancer. TWIST (A, clear cell carci-
noma), HIF1α (B, mucinous carcinoma), and p53 (C, serous carcinoma) are expressed in the nuclei of tumor cells, whereas E-cadherin (D, 
clear cell carcinoma) expression is lost.
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as TWIST, SNAI1, SLUG, and ZWB1.4 TWIST overexpres-
sion has also been identified in various kinds of epithelial tu-
mors and plays a distinct role in tumor progression via the loss 
of E-cadherin expression.6-16
There have been a few other reports showing a correlation 
between TWIST expression and clinical significance in patients 
with OEC.8,9 These previous studies have examined the expres-
sion of TWIST in OEC cases, reporting immunohistochemical 
detection of TWIST expression in about 30–40% of cases. 
TWIST expression was correlated with clinicopathological pa-
rameters and found to be a predictor of poor survival. Hosono et 
al.8 also reported that positive TWIST expression was an inde-
pendent prognostic factor for survival in their multivariate 
analyses. In this study of 123 OEC patients with follow-up, 
positive TWIST expression was detected in 35 of 123 OEC 
cases (28.5%). We found that TWIST expression was correlated 
with higher histologic grades and shorter OS and PFS in OEC 
patients, which is consistent with results from previous studies 
of other malignant tumors, including OEC. In the analysis of 
the histological type-stratified data, TWIST expression tended 
to be higher in the clear cell type of OEC (44.0%), although 
the difference was not significant (p=.240). Kajiyama et al.26 
reported that TWIST expression was not only detected more 
frequently, but was also an independent prognostic factor in the 
clear cell type of OEC. They suggested that TWIST might play 
a role in the mechanisms for poor prognosis and chemoresis-
tance in the clear cell type of OEC.
Table 3. Correlation between TWIST, HIF1α, p53, and E-cadherin
TWIST E-cadherin HIF1α p53
TWIST p-value - .000 .000 .142
c.c - –0.309 0.532 0.168
E-Cadherin p-value - - .322 .041
c.c - - –0.157 –0.219
HIF1α p-value - - - .611
c.c - - - –0.006
HIF1α, hypoxia-inducible factor 1α; C.C., correlation coefficient.
Table 2. Relationship between TWIST, HIF1α, p53, and E-cadherin with clinicopathological factors in patients with OEC (n=123)
Parameter n (%) TWIST expression HIF1α expression p53 expression E-Cadherin reduced expression
Histologic type
   Serous 63 (51.2) 15 (23.8) 16 (25.4) 28 (44.4) 28 (44.4)
   Mucinous 24 (19.5) 7 (29.2) 13 (54.2) 3 (12.5) 16 (66.7)
   Endometrioid 11 (8.9) 2 (18.2) 0 (0) 4 (36.4) 6 (58.3)
   Clear cell 25 (20.4) 11 (44.0) 14 (55.0) 1 (4.0) 13 (52.0)
   p-value .240 .001 .000 .320
Histologic grade
   G1 35 (28.5) 9 (25.7) 15 (42.9) 1 (2.9) 20 (57.1)
   G2 62 (50.4) 12 (19.4) 18 (29.0) 23 (37.1) 35 (56.5)
   G3 26 (21.1) 14 (53.8) 10 (48.5) 12 (46.2) 8 (31.8)
   p-value .004 .357 .000 .063
Nuclear grade
   1 13 (10.6) 3 (23.1) 4 (30.8) 2 (15.4) 6 (46.2)
   2 62 (50.4) 15 (24.2) 19 (30.7) 19 (30.6) 30 (48.4)
   3 48 (39.0) 17 (35.4) 20 (41.7) 15 (31.2) 27 (56.2)
   p-value .391 .459 .507 .664
Mitoses
   <10 52 (42.3) 16 (29.4) 23 (43.1) 3 (4.0) 29 (54.9)
   10-19 41 (33.3) 11 (28.6) 13 (33.3) 16 (39.0) 22 (54.8)
   ≥20 30 (24.4) 8 (23.3) 7 (23.3) 17 (56.7) 12 (40.0)
   p-value .888 .139 .000 .361
Tumor size (cm)
   <10 58 (47.2) 14 (24.1) 16 (27.6) 19 (32.8) 27 (46.6)
   ≥10 65 (52.8) 21 (32.3) 27 (41.5) 17 (26.2) 36 (55.4)
    p-value .424 .131 .435 .369
FIGO stage
   Early (I, II) 63 (51.2) 15 (23.8) 25 (39.7) 7 (11.1) 41 (65.1)
   Advanced (III, IV) 60 (48.8) 20 (33.3) 18 (30.0) 29 (48.3) 22 (36.7)
   p-value .318 .344 .000 .002
Total 123 35 (28.5) 43 (35.0) 36 (29.3) 60 (48.8)
Values are presented as number (%).
HIF1α, hypoxia-inducible factor 1α; OEC, ovarian epithelial cancer; FIGO, Federation of Gynecology and Obstetrics.
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p53 is a tumor suppressor gene that is involved in the regula-
tion of cell growth. Mutations in the p53 gene are among the 
most commonly detected genetic abnormalities in human neo-
plasia. Mutations result in a conformational change in the pro-
tein, which becomes stabilized, thus usually, but not always, al-
lowing for immunohistochemical detection. Although not fully 
Table 4. Univariate analysis of various clinicopathological parameters and the immunoexpression of TWIST, HIF1α, p53, and E-cadherin in 
relation to overall survival (OS) and progression-free survival (PFS)
OS PFS
Alive (n=73) DOD (n=50) p-value Progression-free (n=63) Progression (n=60) p-value
Histologic type .327 .000
   Serous 35 (55.6) 28 (44.4) 21 (33.3) 42 (66.7)
   Mucinous 18 (75.0) 6 (25.0) 19 (79.2) 5 (20.8)
   Endometrioid 7 (63.6) 4 (36.4) 7 (63.6) 4 (36.4)
   Clear 13 (52.0) 12 (48.0) 16 (64.0) 9 (36.0)
Histologic grade .030 .000
   Well differentiated 27 (77.1) 8 (22.9) 28 (80.0) 7 (20.0)
   Moderately differentiated 34 (54.8) 28 (45.2) 28 (45.2) 34 (54.8)
   Poorly differentiated 12 (46.2) 14 (53.8) 7 (26.9) 19 (73.1)
Nuclear grade .155 .071
   1 10 (76.9) 3 (23.1) 10 (76.9) 3 (23.1)
   2 39 (62.9) 23 (37.1) 33 (53.2) 29 (46.8)
   3 24 (50.0) 24 (50.0) 20 (41.7) 28 (58.3)
Mitoses .029 .027
   ≤10/10 HPF 37 (72.5) 15 (27.5) 34 (65.4) 18 (34.6)
   >10 and ≤20/10 HPF 18 (43.9) 23 (56.1) 17 (41.5) 24 (58.5)
   >20/10 HPF 18 (60.0) 12 (40.0) 12 (40.0) 18 (60.0)
Tumor size (cm) .141 .002
   <10 30 (51.7) 28 (48.3) 21 (36.2) 37 (63.8)
   ≥10 43 (66.2) 22 (33.8) 42 (64.6) 23 (35.4)
FIGO stage .000 .000
   I– II 52 (82.5) 11 (17.5) 56 (88.9) 7 (11.1)
   III– IV 21 (35.0) 39 (65.0) 7 (11.7) 53 (88.3)
TWIST expression .001 .027
   No 61 (69.3) 27 (30.7) 51 (58.0) 37 (42.0)
   Yes 12 (34.3) 23 (65.7) 12 (34.3) 23 (65.7)
E-Cadherin .000 .001
   No 22 (36.7) 38 (63.3) 21 (35.0) 39 (65.0)
   Yes 51 (81.0) 12 (19.0) 42 (66.7) 21 (33.3)
HIF1α expression .185 .850
   No 51 (63.8) 29 (36.2) 40 (50.0) 40 (50.0)
   Yes 22 (51.2) 21 (48.8) 23 (53.5) 20 (46.5)
p53 expression .004 .000
   No 59 (67.8) 28 (32.2) 56 (64.4) 31 (35.6)
   Yes 14 (38.9) 22 (61.1) 7 (19.4) 29 (80.6)
TWIST/E-cadherin .003 .127
   No 64 (66.7) 32 (33.3) 53 (55.2) 43 (44.8)
   Yes 9 (33.3) 18 (66.7) 10 (37.0) 17 (63.0)
TWIST/p53 .082 .000
   No 68 (61.3) 41 (38.7) 62 (56.9) 47 (43.1)
   Yes 5 (35.7) 9 (64.3) 1 (7.1) 13 (92.9)
HIF1α/TWIST/E-cadherin expression .011 .459
   No 67 (64.4) 37 (35.6) 55 (52.9) 49 (47.1)
   Yes 6 (31.6) 13 (68.4) 8 (42.1) 11 (57.9)
HIF1α, hypoxia-inducible factor 1α; DOD, died of disease; HPF, high power field; FIGO, Federation of Gynecology and Obstetrics.
defined, recent evidence has indicated that TWIST may inter-
fere with the p53 tumor suppressor pathway.23,24 TWIST has 
previously been shown to reduce the activity of the p53 pro-
moter as well as mediate suppression on p53 target sequences. 
Wang et al.18 demonstrated that increased TWIST was respon-
sible for the development of acquired resistance to chemothera-
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Table 5. Multivariate analysis of several clinicopathological factors in relation to the OS of patients with OEC
Variables Grouping p-value Hazard ratio 95% of CI
Histologic grade I vs II– IV .862 0.672 0.216–2.091
FIGO stage I, II vs III, IV .003 0.306 0.140–0.670
Mitoses Low vs high .268 1.853 0.833–4.121
TWIST expression No vs yes .000 0.061 0.013–0.278
p53 expression No vs yes .490 0.788 0.400–1.550
TWIST/E-cadherin No vs yes .054 5.457 0.971–30.657
HIF1a/TWIST/E-cadherin No vs yes .860 1.178 0.190–7.312
OS, overall survival; OEC, ovarian epithelial cancer; CI, confidence interval; FIGO, Federation of Gynecology and Obstetrics.
peutic drugs and microtubule-disrupting agents, including pa-
clitaxel. TWIST may protect from apoptosis mediated by p53 
in response to DNA damage induced by radiation and drugs. 
Chemoresistance, as well as the facilitation of metastasis by 
TWIST, may be the underlying mechanism linking TWIST 
expression with an unfavorable prognosis. In this study, we 
found that p53 expression showed no correlation with TWIST 
expression, but an inverse correlation with E-cadherin expres-
sion was established. Interestingly, co-expression of TWIST and 
p53 (13/14 cases, 92.9%) showed unfavorable PFS compared 
with no co-expression (47/109 cases, 43.1%) (p=.000). These 
results suggest that TWIST and p53 could cooperate with each 
other to facilitate cancer progression, and p53 could have an 
important role in EMT.
E-Cadherin plays a critical role in regulating the balance of 
cell-cell adhesion and cell motility, placing it in a significant po-
sition to regulate tumor cell proliferation and invasion. Some 
studies have identified that reduced E-cadherin expression is as-
sociated with more aggressive epithelial tumors.9,12,17,21 TWIST 
binds the E-cadherin promoter and inhibits E-cadherin tran-
scription levels, which modulate EMT in cancer progression. An 
inverse correlation between TWIST upregulation and E-cad-
herin downregulation was also observed in several types of ma-
lignancies.5,10 However, Yoshida et al.27 demonstrated that there 
was not an inverse correlation between the expression of E-cad-
herin and TWIST in OEC. In this study, reduced E-cadherin 
expression was associated with advanced FIGO stage and poor 
OS and PFS. Our results are consistent with the observation that 
E-cadherin has been described in patients with advanced stage 
OEC and is associated with poor prognosis.9 Moreover, a signifi-
cant inverse relationship was observed between these two mark-
ers in this study, and we showed that TWIST(+)/E-cadherin(–) 
cases are also associated with poor prognosis.
For cancer progression, intratumoral hypoxia followed by the 
Fig. 2. Kaplan-Meier analysis of overall survival (OS) and progression-free survival (PFS) in ovarian epithelial cancer according to the immu-
noexpression of TWIST. TWIST expression is associated with poorer OS and PFS.
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activation of HIF1α is one of the most important mechanisms 
promoting tumor aggressiveness, leading to metastasis and pa-
tient mortality. Recent results have shown the upregulation of 
mRNA and protein levels of TWIST in different cell lines under 
hypoxia and constitutive expression of HIF1α.19,20 TWIST can 
be a direct target of HIF1α due to the functional presence of a 
hypoxia-related element located in the proximal promoter of 
TWIST.20 The survival analysis in the aforesaid report demon-
strated the worst prognosis and shortest metastasis-free period in 
HNSCC patients with HIF1α, TWIST, and Snail co-expression, 
indicating that the co-expression of these markers in tumor tis-
sues could be used as a valuable marker to predict metastasis and 
prognosis in HNSCC patients. In a study by Feng et al.,21 the 
overexpression of HIF1α and TWIST was frequently detected in 
endometrial endometrioid carcinoma (EEC) samples, and they 
were associated with aggressive tumor characteristics, such as 
higher histologic grades, deeper myometrial invasion, and lymph 
node metastasis. The interesting findings of the study were that 
TWIST-positive cases exhibited increased expression of HIF1α 
and reduced expression of E-cadherin in EEC. The researchers 
suggested that the HIF1α/TWIST/E-cadherin pathway may 
play a critical role in the progression of EEC. Our study showed 
a positive association between HIF1α and TWIST expression 
(ɤ=0.407, p=.000) and a negative association between TWIST 
and E-cadherin expression (ɤ=–0.358, p=.000). Moreover, al-
tered expression of the HIF1α/TWIST/E-cadherin pathway was 
associated with poor OS in OEC in the univariate analysis.
In summary, we show that increased expression of TWIST, 
HIF1α, and p53 and reduced expression of E-cadherin are fre-
quently observed in OEC cases. TWIST expression was associ-
ated with poor OS in both the univariate and multivariate anal-
yses. Therefore, TWIST may serve as a useful marker in pa-
tients with OEC who are likely to have an unfavorable clinical 
outcome. Our results support the critical role of the HIF1α/
TWIST/E-cadherin pathway in cancer progression and the ac-
quisition of the metastatic phenotype in OEC. Therefore, path-
ways involved in hypoxia-mediated EMT, such as the HIF1α/
TWIST/E-cadherin pathway, may be possible candidates for 
molecular targeting in the future treatment of OEC. Further 
studies are needed to clarify the role and molecular mechanisms 
underlying of the HIF1α/TWIST/E-cadherin pathway in tu-
mor progression.
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